Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
OUTCOMES OF ANTIEMETIC THERAPY AFTER THE ADMINISTRATION OF HIGH-DOSE ANTINEOPLASTIC AGENTS
Autore:
TROVATO JA; STULL DM; FINLEY RS;
Indirizzi:
MARLENE & STEWART GREENEBAUM CANC CTR,DEPT CLIN PHARM,ROOM N9E04,22 SGREENE ST BALTIMORE MD 21201 UNIV MARYLAND,DEPT PHARM PRACTICE & SCI,SCH PHARM BALTIMORE MD 21201 NEW YORK HOSP,CORNELL MED CTR,ONCOL PHARM SERV NEW YORK NY 10021 PHILADELPHIA COLL PHARM & SCI,DEPT PHARM PRACTICE & PHARM ADM PHILADELPHIA PA 19104
Titolo Testata:
American journal of health-system pharmacy
fascicolo: 12, volume: 55, anno: 1998,
pagine: 1269 - 1274
SICI:
1079-2082(1998)55:12<1269:OOATAT>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
CISPLATIN-INDUCED EMESIS; CHEMOTHERAPY-INDUCED NAUSEA; DOUBLE-BLIND; DELAYED EMESIS; INTRAVENOUS ONDANSETRON; ORAL ONDANSETRON; PHASE-II; METOCLOPRAMIDE; PROPHYLAXIS; PREVENTION;
Keywords:
ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOSAGE; DOSAGE SCHEDULES; GRANISETRON; NAUSEA; OUTCOMES; TOXICITY; VOMITING;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
18
Recensione:
Indirizzi per estratti:
Citazione:
J.A. Trovato et al., "OUTCOMES OF ANTIEMETIC THERAPY AFTER THE ADMINISTRATION OF HIGH-DOSE ANTINEOPLASTIC AGENTS", American journal of health-system pharmacy, 55(12), 1998, pp. 1269-1274

Abstract

Patterns of antiemetic therapy and its outcomes in patients undergoing high-dose antineoplastic therapy were studied. The study, conducted at a cancer center, included both a retrospective evaluation of patients undergoing highly emetogenic high-dose chemotherapy with peripheralblood stem-cell rescue between November 1994 and December 1995 and a concurrent evaluation of patients treated between January and May 1996. During the study period the recommended antiemetic regimen for highly emetogenic chemotherapy was a single dose of granisetron 1 mg i.v. daily 30 minutes before treatment on days of chemotherapy. Severity of nausea and vomiting during both the acute phase (from day 1 of chemotherapy to 24 hours after its completion) and delayed phase (from 24 hours to five days after the end of chemotherapy) was graded according tothe Common Toxicity Criteria Grading Scale. A total of 59 patients were evaluable; 41 were reviewed retrospectively, and 18 were reviewed concurrently. On day 1 of the acute phase, 53 patients (90%) had no vomiting and 51 patients (86%) had no nausea. The frequency and severity of nausea and vomiting increased on successive acute-phase days, and it was necessary to add other antiemetics. Nausea and vomiting continued to be significant problems throughout the delayed phase; 32 (54%) ofthe patients had a maximum of grade 3 nausea, and 29 patients (49%) had a maximum of grade 2 vomiting. Substantial numbers of patients who received selective serotonin type 3 receptor antagonists before high-dose antineoplastic agents had significant nausea and vomiting that required the addition of other antiemetics.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/07/20 alle ore 15:24:20